Shares of Envista Holdings Co. (NYSE:NVST – Get Free Report) have been assigned a consensus recommendation of “Hold” from the fifteen ratings firms that are currently covering the firm, MarketBeat Ratings reports. Three research analysts have rated the stock with a sell recommendation, nine have assigned a hold recommendation and three have given a buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $19.63.
NVST has been the subject of a number of recent analyst reports. Piper Sandler decreased their price objective on shares of Envista from $18.00 to $16.00 and set a “neutral” rating for the company in a report on Tuesday, July 30th. Bank of America lowered their price target on Envista from $22.00 to $19.00 and set a “buy” rating on the stock in a report on Thursday, August 8th. Robert W. Baird reduced their price objective on Envista from $19.00 to $17.00 and set a “neutral” rating for the company in a report on Monday, July 22nd. JPMorgan Chase & Co. downgraded shares of Envista from an “overweight” rating to a “neutral” rating and dropped their price target for the company from $23.00 to $16.00 in a report on Thursday, August 8th. Finally, Stifel Nicolaus decreased their price objective on shares of Envista from $20.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, July 30th.
View Our Latest Research Report on NVST
Envista Price Performance
Envista (NYSE:NVST – Get Free Report) last released its quarterly earnings data on Wednesday, August 7th. The company reported $0.11 earnings per share for the quarter, missing analysts’ consensus estimates of $0.27 by ($0.16). The firm had revenue of $633.10 million for the quarter, compared to the consensus estimate of $646.88 million. Envista had a negative net margin of 52.25% and a positive return on equity of 4.86%. The firm’s revenue for the quarter was down 4.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.43 earnings per share. As a group, equities analysts expect that Envista will post 0.69 EPS for the current fiscal year.
Insider Activity at Envista
In related news, CFO Eric D. Hammes purchased 24,532 shares of Envista stock in a transaction on Monday, August 12th. The stock was acquired at an average price of $16.33 per share, for a total transaction of $400,607.56. Following the completion of the transaction, the chief financial officer now directly owns 24,532 shares in the company, valued at $400,607.56. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.30% of the stock is owned by company insiders.
Hedge Funds Weigh In On Envista
A number of hedge funds have recently modified their holdings of NVST. GAMMA Investing LLC lifted its stake in shares of Envista by 69.8% during the 3rd quarter. GAMMA Investing LLC now owns 1,766 shares of the company’s stock valued at $35,000 after buying an additional 726 shares in the last quarter. Blue Trust Inc. lifted its position in shares of Envista by 69.7% in the third quarter. Blue Trust Inc. now owns 1,957 shares of the company’s stock valued at $39,000 after acquiring an additional 804 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its position in shares of Envista by 50.8% in the third quarter. Allspring Global Investments Holdings LLC now owns 2,161 shares of the company’s stock valued at $43,000 after acquiring an additional 728 shares in the last quarter. Versant Capital Management Inc boosted its stake in shares of Envista by 1,420.3% in the second quarter. Versant Capital Management Inc now owns 3,147 shares of the company’s stock worth $52,000 after acquiring an additional 2,940 shares during the period. Finally, Innealta Capital LLC purchased a new stake in shares of Envista during the second quarter worth about $78,000.
About Envista
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.
Read More
- Five stocks we like better than Envista
- How to buy stock: A step-by-step guide for beginners
- Is Spotify Stock Poised to Soar? Options Traders Think So
- How to Capture the Benefits of Dividend Increases
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.